Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an ...

Diabetes continues to emerge as a critical public health challenge globally and in Thailand, with alarming increases among children and youth. This includes both Type 1 diabetes, which requires ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over ...

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

French pharmaceutical giant Sanofi announced on Tuesday that Tzield, the world's first and only therapy approved by the ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

The Ministry of Health is partnering with Sanofi to boost immunisation drives and public awareness from 2025-2027.